Don’t let asthma control your patients

Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short acting β2-agonists.
  • patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.11

Why choose Relvar?

Tick icon

25% more patients see improvement vs other commonly used ICS/LABAs, 14% absolute difference**2,10

24-H icon

Sustained efficacy for 24 hours and long-lasting anti-inflammatory effect3-5

Ellipta device icon

Ellipta device

Relvar: a lower carbon footprint than MDIs8

In this day and age, it’s important to be informed as to the environmental impact of the treatments we prescribe our patients.

That’s why we’re proud to say that, compared with other asthma devices, Relvar Ellipta has one of the lowest carbon footprints.8

Annual carbon footprints (kg CO2e) for different combinations of Relvar, Seretide and Ventolin and annual footprint reduction of different actions

annual carbon footprints graph

This graph has been independently created by GSK from the original data. The same results were first published in Janson C, et al. Thorax 2020;75:82–84.

Contribution of phases in the life cycle of different inhaler devices to their individual carbon footprint (net kg CO2e/per pack) and annual carbon footprints of each device8

life cycle contributions graph

*if using on average two doses per day

Who can benefit from Relvar?

‌Hypothetical patients used for illustrative purposes.

Discover more about Relvar


**This was an open-label, randomised, controlled, two-arm effectiveness study in > 4,000 patients aged ≥18 years with symptomatic asthma measured by the Asthma Control Test (ACT) - a clinically validated patient questionnaire which reflects the previous 4 weeks. In a subset analysis the proportion of responders prescribed Relvar vs. continuing on usual care at 6 months showed 25% relative difference in responders; 14% absolute difference. Other ICS/LABAs commonly prescribed which were Seretide (fluticasone proprionate/salmeterol, 30%), Symbicort (budesonide/formoterol, 15%), Fostair (beclomethasone/formoterol, 12%), in the primary efficacy analysis (PEA) population at 24 weeks. It is worth noting that in a separate double-blind non-inferiority RCT in c. 1500 patients vs Seretide, the ACT score favoured Relvar but did not reach significance [0.2 (95% CI -0.1 - 0.5)]: this study provides further context around other data relating to this endpoint. The primary endpoint was the proportion of patients who achieved an improvement in ACT score from baseline of ≥3 or a total ACT score of ≥ 20, in patients in the primary efficacy analysis (PEA) population initiated on Relvar vs. continuing on usual care at 24 weeks. In this study there was no difference in serious adverse events reported between Relvar and usual care. The most common serious adverse events of special interest were cardiovascular disease, asthma and bronchospasm, and pneumonia.


ACT, Asthma Control Test; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; PEA, primary effectiveness analysis; PRD, proactive regular dosing. 
CO2e, annual carbon footprint; MDI, metered dose inhaler.


  1. Global Datasheet Fluticasone furoate/vilanterol: v11, May 2021.
  2. Woodcock A, et al. Lancet 2017;390:2247–2255.
  3. Bernstein DI, et al. J Asthma 2015;52:1073–1083.
  4. Braithwaite I, et al. Respir Med 2016;119:115–121.
  5. Bardsley G, et al. Respir Res 2018;19:133.
  6. Svedsater H, et al. NPJ Prim Care Respir Med 2014;24:14019.
  7. Parimi M, et al. Adv Ther 2020;37:2916–2931.
  8. Janson C, et al. Thorax [1] 2020;75:82–84.
  9. Daley-Yates PT. Br J Clin Pharmacol 2015;80:372–380.
  10. DoF: RF/FFT/0019/18.
  11. Relvar SmPC.

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

© 2023 GSK group of companies or its licensor. RELVAR was developed in collaboration with INNOVIVA.

Trademarks are owned by or licensed to the GSK group of companies.

Innoviva logo

February 2023 | PM-GB-FFV-WCNT-220001 (V1.0)